Incidence and consequences of post-transplantation lymphoproliferative disorders

Journal of Nephrology

Volumn 10, Issue 3, 1997, Pages 136-145

  Boubenider, Samir ^a   Hiesse, Christian ^a   Goupy, Christophe ^a   Kriaa, Fayçal ^a   Marchand, Sylvie ^a   Charpentier, Bernard ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Cyclosporin; Epstein Barr virus; Incidence; Lymphomas; Lymphoproliferative disorders; OKT3; Transplantation

Indexed keywords

B LYMPHOCYTE ANTIBODY; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; OKT 3; TACROLIMUS;

B LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; POSTOPERATIVE COMPLICATION; REVIEW; RISK ASSESSMENT; VIRUS INFECTION;

HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; RISK FACTORS;

EID: 0030853363     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Penn I. Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996; 28: 876-8.
2. Hanto DC, Birchenbach M, Frizzera G, Gajl-Pecsalska KJ, Simmons RL, Schubach WH. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus-associated B-cell proliferation by immunoglobulin gene rearrangement analysis. Transplantation 1989; 47: 458-64.
3. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr. Prob Surg 1988; 25: 367-72.
4. Sheil AGR, Disney APS, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-4.
5. Hiesse C, Kriaa F, Rieu P, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: Analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27: 276-7.
6. Montagnino G, Lorca E, Tarantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution: Comparison with normal population and with patients under dialytic treatment. Clin Transplantation 1996; 10: 461-9.
7. London NJ, Farmery SM, Will EJ, Davidson AM, Lodge PJA. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403-6.
8. Birkeland SA. Malignant tumours in renal transplant patients: The Scandia Transplant Material. Cancer 1983; 51: 1571-5.
9. Penn I. The changing pattern of post-transplant malignancies. Transplant Proc 1991; 23: 1101-3.
10. Kilen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; (Suppl 1A) 78: 44.
11. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 25: 1767-9.
12. Tokoro Y, Asano T, Nakagouri T, et al. A statistical study of cancer incidence in renal transplant patients. Transplant Proc 1992; 24: 1588-90.
13. Cockfield S, Preiksaitis JK, Jewell LD, Parfey NA. Post-transplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplantation 1993; 56: 88-96.
14. Alfrey EJ, Friedman AL, Grossman A, et al. Two distinct patterns of post-transplantation lymphoproliferative disorder (PTLD): early and late onset. Clin Transplantation 1992; 6: 246-8.
15. Preiksaitis JK. Lymphoproliferative disorders in renal transplant recipients: virologic aspects. Clin Transplantation 1992; 6: 235-9.
16. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center J Clin Oncol 1995; 13: 961-8.
17. Nalesnik MA, Locker J, Jaffe R, et al. Experience with post-transplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplantation 1992; 6: 249-52.
18. Calne RY, Rolles K, White DJS, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet 1979; 2: 1033-6.
19. The Canadian Multicenter Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transpolantation. N Engl J Med 1983; 309: 809-15.
20. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983; 2: 986-9.
21. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43: 32-5.
22. Frei U, Bode U, Repp H, et al. Malignancies under cyclosporine after kidney transplantation. Analysis of a 10-year period. Transplant Proc 1993; 25: 1394-6.
23. Grūber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL. De novo cancer in cyclosporine-treated and non-cyclosporine treated adult primary renal allograft recipients. Clin Transplantation 1994; 8: 388-91.
24. Beveridge T, Krupp T, Mc Kiblin C, et al. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy. Lancet 1984; 1: 788.
25. Wilkinson AH, Smith JL, Lawrence G, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and predinisone. Transplantation 1989; 47: 293-6.
26. Legendre C, Kreis H. Effect of immunosuppression on the incidence of lymphoma formation. Clin Transplantation 1992; 6: 220-2.
27. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased risk of lymphoproliferative disorders following the use of OKT3 in cardiac transplantation. Clin Transplantation 1992; 6: 253-9.
28. Ratkovec RM, O'connell JB, Bristow MR, et al. Post-transplant lymphoproliferative disease in cardiac transplant patients receiving OKT3 therapy. Clin Transplantation 1992; 6: 260-4.
29. Batiuk TD, Barry JM, Bennett MM, Meyer DM, Tolzman D, Norman DJ. Incidence and type of cancer following the use of OKT3: A single center experience with 557 organ transplants. Transplant Proc 1993; 25: 1391.
30. Opelz G, Henderson R, for the Collaborative Transplant Study. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-6.
31. Muir C, Watherhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents, Lyon: IARC 1987.
32. Jirasiritham S, Jirasiritham S, Sumerthkul V, Chiewsilp P. Incidence of post kidney transplantation in Thailand. Transplant Proc 1996; 28: 1586-7.
33. Kim MS, Kim YS, Kim CKO, Park K. De novo cancer in transplant recipients. Transplant Proc 1996; 28: 1651-2.
34. Qunibi WY, Barri Y, Al-Furayh V, et al. Kaposi's sarcoma in renal transplant recipients: a report on 26 cases from a single institution. Transplant Proc 1993; 25: 1402-5.
35. Boubenider SA, Al-Suleiman M, Dhar JM, Al-Khader AA. Post renal transplantation non-Hodgkin's lymphoma: local experience and review of the literature. Ann Saudi Med 1992; 12: 174-7.
36. Qunibi WY, Akhtar M, Sheth K, et al. The most common tumour after renal transplantation in Saudi Arabia. Am J Med 1988; 84: 225-32.
37. Gaya SBM, Rees AJ, Lechler G, Williams G, Mason PD. Malignant disease in patients with long-term renal transplants. Transplantation 1995; 59: 1705-9.
38. Shell AGR. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 1992; 24: 1275-9.
39. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency and B-cell lymphoproliferation. Transplantation 1985; 39: 461-71.
40. Opelz G. Are post-transplant lymphomas inevitable? Nephrol Dial Transplant 1996, 11: 1952-5.
41. Gorp JU, Doornewaard H, Verdonck LF, Klopping C, et al. Posttransplant T-celllymphoma. Cancer 1994; 73: 3064-72.
42. Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc 1995; 27: 38-40.
43. Hibberd PL, Rubin RH. Antiviral therapy. An anti-malignancy strategy for transplant recipients? Clin Transplantation 1992; 6: 240-5.
44. Macleod AM, Thomson AW. FK 506: an immunosuppressant for the 1990s. Lancet 1991; 337: 25-7.
45. Penn I. Immunosuppression - A contributory factor in lymphoma formation. Clin Transplantation 1992; 6: 214-9.
46. Thomas JA, Crawford DH, Burke M. Clinicopathologic implication of Epstein-Barr virus related B cell lymphoma in immunocompromised patients. J Clin Pathol 1995; 48: 287-90.
47. Klein G. The Epstein-Barr virus and neoplasia. N Engl J Med 1975; 293: 1353-6.
48. Nagington J. Cyclosporin A immunosuppression and Epstein-Barr antibody. Lancet 1981; 2: 196-7.
49. Ho M, Miller G, Atchinson RW, et al. Epstein-Barr virus infection and DNA hybridization studies in post-transplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876-86.
50. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719-27.
51. Bieber CP, Heberling RL, Jamieson SW, et al. Lymphoma in cardiac transplant recipients associated with cyclosporin A, prednisone and anti-thymocyte globulin (ATG). in: Immune deficiency and cancer: Epstein-Barr virus and lymphoproliferative malignancies. Plenum publishing corporation; New-York 1984.
52. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35: 35-42.
53. Yao QY, Rickinson AB, Gaston JSH, Epstein MA. In vitro analysis of the Epstein-Barr virus: host balance in long-term renal allograft recipients. Int J Cancer 1985; 35: 43-9.
54. Graig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 265-76.
55. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991: 65: 1097-8.
56. Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumours arising after organ transplantation. Am J Pathol 1989; 135: 377-87.
57. Thomas JA, Hotchin NA, Allday MJ, et al. Immunohistology of Epstein-Barr virus-assicated antigens in B-cell disorders from immunocompromised individuals. Transplantation 1990; 49: 944-53.
58. Ambinder RF, Lambe BC, Mann RB, et al. Oligonucleotides for polymerase chain reaction amplification and hybridization detection of Epstein-Barr virus DNA in clinical specimens. Mol Cell Probes 1990; 4: 397-407.
59. Fukuda M, Aikawa I, Ohmori Y, et al. Chromosome aberrations in kidney transplant recipients. Transplant Proc 1987; 19: 2245-7.
60. Hattori A, Perera MIR, Witkowski LA, Kunz HW, Gill TJ III, Shinozuka H. Accelerated development of spontaneous thymic lymphomas in male AKR mice receiving cyclosporine. Transplantation 1986; 41: 784-8.
61. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: some anti-neoplastic and immunosuppressive agents, World Health Organisation. Lyon: IARC, 1981, 26.
62. Demetris AJ, Nalesnik MA, Kunz HW, Gill TJ III, Shinozuka H. Sequential analyses of the development of lymphoproliferative disorders in rats receiving cyclosporine. Transplantation 1984; 38: 239-46.
63. Barkholt L, Billing H, Juliusson G, et al. B-cell lymphoma in transplanted liver: clinical, histological, and radiological manifestations. Transpl Int 1991; 4: 8-11.
64. Maeda K, Hawkins ET, Oh HK, Kini SR, Van Dyke DL. Malignant lymphoma in transplanted renal pelvis. Arch Pathol Lab Med 1986; 110: 626-9.
65. Penn I. Host origin of lymphoma in organ transplant recipients. Transplantation 1979; 27: 14.
66. Shapiro RS, MC Clain K, Frizzera G, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-43.
67. Gossett TC, Gale RP, Fleischman H, et al. Immunoblastic sarcoma in donor cells after bone marrow transplantation. N Engl J Med 1979; 300: 904-7.
68. Randhawa PS, Yousem SA. Epstein-Barr virus-associated lymphoproliferative disease in a heart-lung allograft. Transplantation 1990; 43: 126-30.
69. Hegele RG, Bicknell SG, Bailey DJ, Cameron RG. In situ hybridization for the Y chromosome reveals a donor origin for a posttransplantation lymphoproliferative disorder in a sex-mismatched hepatic allograft. Arch Pathol Lab Med 1994; 118: 795-6.
70. Weissman DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumours of host origin. Am J Clin Pathol 1995; 103: 748-55.
71. Gassel AM, Westhal E, Hansmann ML, Leimenstoll G, Gassel HJ. Malignant lymphoma of donor origin after renal transplantation: a case report. Hum Pathol 1991; 22: 1291-3.
72. Gambacorta M, Bonacina E, Falini B, Sebatini E, Pileri S. Malignant lymphoma in the recipient of a heart transplant from a donor with malignant lymphoma: lymphoma transplantation or de novo disease? Transplantation 1991; 51: 920-2.
73. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262-79.
74. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913-8.
75. Cleary ML, Warnke R, Sklar J, et al. Monoclonalty of lymphoproliferative lesions in cardiac transplant recipients. N Engl J Med 1984; 370: 477-82.
76. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173-91.
77. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-65.
78. Randhawa PS, Youssem SA, Paradis IL, Dauber JA, Griffith BP, Locker J. The clincal spectrum, pathology and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients. Am J Clin Pathol 1989; 92: 177-85.
79. Youssem SA, Randhawa P, Locker J, et al. Posttransplantation lymphoproliferative disorders in heart- lung transplant recipients: primary presentation in the allograft, Hum Pathol 1989; 20: 361-9.
80. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-7.
81. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240-4.
82. Hanto DW, Gajl-Pecsalska KG, et al. EBV-induced polyclonal and monoclonal B-cell lymphoproliferative disease occurring after renal transplantation. Ann Surg 1983; 198: 356-69.
83. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23: 1106-7.
84. Kalra PA, Wood GN, O'Donoghue DJ, et al. Complete regression of recurrent diffuse malignant lymphoma after withdrawal of cyclosporin A in renal transplant recipient. Nephrol Dial Transplant 1994; 994: 1197-200.
85. Touraine JL, Garnier JL, Lafrançois N, et al. Severe lymphoproliferative disease and Kaposi sarcoma in transplant patients. Transplant Proc 1989; 21: 3197-8.
86. Colby BM, Shaw JE, Elion GB, Pagano JC. Effect of acyclovir (9-(2-hydroxyethoxymethyl) guarine on Epstein-Barr virus DNA replication. J Virol 1980; 34: 560-8.
87. Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB. The Epstein-Barr virus: host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy. Int J Cancer 1989; 43: 61-6.
88. Sullivan JL, Byron KS, Brewster FE, Sakamoto K, Shaw JE, Pagano JS. Treatment of life-threatening Epstein-Barr virus infection with acyclovir. Am J Med; 73 (Suppl): 262-6.
89. Martin JC, Dvorac CA, Smee DF, Matthews TR, Verheyden JPH. 9-(1,3-dihydroxy-2-propoxy) methyl) guanine: A new potent and selective antiherpes agents. J Med Chem 1983; 26: 759-61.
90. McGee DPC, Martin JC, Smee DF, Matthews TR, Verheyden JPH. Synthesis and antiherpes simplex virus activity of 9-(1,3 dihydroxy-2-propoxy) methyl) guanine. J Med Chem 1985; 28: 1242-5.
91. Lin JL, Smith MC, Pagano JS. prolonged inhibitory effect of 9- (1,3 dihydroxy-2-propoxy) methyl) guanine against replication of Epstein-Barr virus. J Virol 1984; 50: 50-5.
92. Mar EC, Cheng VC, Huang ES. Effect of of 9-(1,3 dihydroxy-2-propoxy) methyl) guanine for cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1983; 24: 518-21.
93. Pirsch JD, Stratta RJ, Sollinger HW, et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86: 241-4.
94. Swinnen LJ, Constanzo-Nordin MR, Fischer RI. ProMace-CytaBOM induces durable complete remissions in post transplant lymphoma. Pro AM Soc Clin Oncol 1992; 11: 318.
95. Garrett TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993; 72: 2782-5.
96. Blanche S, Deist LE, Veder F, et al. Treatment of severe Epstein-Barr virus-induced polyclonal B. Lymphocyte proliferation by anti B-cell monoclonal antibodies: two cases after HLA-mismatched bone marrow transplantation. Ann Int Med 1988; 108: 199-203.
97. Fischer A, Blanche S, Le Bidoix J, et al. Anti B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451-6.
98. Antoine C, Stevenson G, Nochy D, Belec L, Duboust A, Glotz D. Remission complete de 3 lymphoproliferations B, EBV induites par anticorps monoclonaux chimériques. Transplant Proc 1997 (in press).
99. Garnier JL, Berger F, Martin X, et al. Post-transplant B-cell lymphomas: correlation of late stage B-cell differentiation and progression of disease, treatment with chimeric monoclonal antibody. Transplant Proc 1995; 27: 1777-8.
100. Shapiro RS, Chavenet A, McGuire W, Pearson A, McGlave P. Treatment of B-cell lymphoproliferative disorders with interferon-alpha and intravenous gammaglobulin. N Engl J Med 1988; 318: 1334.
101. Taguchi Y, Purtilo DT, Okano M. Effect of intravenous immunglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorders in a liver transplant recipient. Transplantation 1994; 57: 1813-5.
102. Okano M, Purtilo DT. Interferons and Epstein-Barr virus infection. In: Jaffe HS, Bucalo LR, Sherwin SA, eds, Anti-infective applications of interferon-gamma. New York: Dekker, 1992, 213.
103. Stephan JC, Le Deist F, Blanche S, et al. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of B-cell-specific monoclonal antibody. Transplantation 1992; 54: 246-9.
104. Ben Hmida M, Mhiri C, Hachicha J, et al. Unsuccessful intrathecal treatment with anti-B cell monoclonal antiboides (anti-CD 21). Transplant Proc 1995; 27: 1779-80.
105. Purtilo DT. Malignant lymphomas in children with primary immunodeficiency disease. Clin Transplantation 1992; 6: 223-6.
106. Shell AGR. Malignancy in organ transplantation patients. Transplant Proc 1996; 28: 1162.